Evidence map›Paper›PMID 31819116›Full record

ArticleScientific reports2019

Integrative proteomics and phosphoproteomics in pulmonary arterial hypertension.

Weiling Xu, Suzy A A Comhair, Ruoying Chen, Bo Hu, Yuan Hou, Yadi Zhou, Lori A Mavrakis, Allison J Janocha, Ling Li, Dongmei Zhang and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.

  1. A Cross-Species and Sex-Specific Meta-Analysis of Transcriptomic Studies of Pulmonary Hypertension.American journal of respiratory cell and molecular biology · 2025
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Weiling XuLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America. xuw@ccf.org.ORCID http://orcid.org/0000-0003-1572-4311
Suzy A A ComhairLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Ruoying ChenLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Bo HuLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Yuan HouLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Yadi ZhouLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Lori A MavrakisLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Allison J JanochaLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Ling LiLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Dongmei ZhangLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Belinda B WillardLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Kewal AsosinghLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Feixiong ChengLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Serpil C ErzurumLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America. erzurus@ccf.org.
Cleveland Clinic Lerner College of Medicine · USCleveland Clinic · US

Funding

Pulmonary Vascular Disease Phenomics Program (PVDOMICS) Data Coordinating CenterU01HL125177 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI BECK, GERALD J, ERZURUM, SERPIL C. · 2014 to 2020
$20.0M
Pulmonary Hypertension Breakthrough InitiativeR24HL123767 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ALDRED, MICHEALA A, ERZURUM, SERPIL C. · 2014 to 2017
$10.1M
NITRIC OXIDE PRODUCTION AND REACTIONS IN THE LUNGR01HL060917 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI Serpil C. Erzurum · 1999 to 2026
$6.3M
Redox Determinants of Severe AsthmaR01HL069170 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI ERZURUM, SERPIL C. · 2001 to 2010
$5.1M
Nitric Oxide in Pulmonary HypertensionR37HL060917 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C. · 2009 to 2018
$3.9M
High-End Instrumentation (HEI) Grant Program (S10)S10OD023436 · OD · CLEVELAND CLINIC LERNER COM-CWRU · PI WILLARD, BELINDA BELLE · 2017 to 2017
$873k
LTQ-Orbitrap Velos instrumentS10RR031537 · NCRR · CLEVELAND CLINIC LERNER COM-CWRU · PI WILLARD, BELINDA BELLE · 2011 to 2011
$600k
NCRR NIH HHS S10 RR031537NHLBI NIH HHS R01 HL060917NHLBI NIH HHS R01 HL069170NIH HHS S10 OD023436U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL060917
6 · The paper itself

Abstract

Pulmonary arterial endothelial cells (PAEC) are mechanistically linked to origins of pulmonary arterial hypertension (PAH). Here, global proteomics and phosphoproteomics of PAEC from PAH (n = 4) and healthy lungs (n = 5) were performed using LC-MS/MS to confirm known pathways and identify new areas of investigation in PAH. Among PAH and control cells, 170 proteins and 240 phosphopeptides were differentially expressed; of these, 45 proteins and 18 phosphopeptides were located in the mitochondria. Pathologic pathways were identified with integrative bioinformatics and human protein-protein interactome network analyses, then confirmed with targeted proteomics in PAH PAEC and non-targeted metabolomics and targeted high-performance liquid chromatography of metabolites in plasma from PAH patients (n = 30) and healthy controls (n = 12). Dysregulated pathways in PAH include accelerated one carbon metabolism, abnormal tricarboxylic acid (TCA) cycle flux and glutamate metabolism, dysfunctional arginine and nitric oxide pathways, and increased oxidative stress. Functional studies in cells confirmed abnormalities in glucose metabolism, mitochondrial oxygen consumption, and production of reactive oxygen species in PAH. Altogether, the findings indicate that PAH is typified by changes in metabolic pathways that are primarily found in mitochondria.

Indexed as

AdultArginineCitric Acid CycleComputational BiologyEndothelial CellsFemaleGlucoseHumansLungLung TransplantationMaleMetabolomicsMiddle AgedMitochondriaNitric OxideOxidative StressArginineGlucoseNitric OxidePeptidesPhosphoproteinsProteomeReactive Oxygen Species

Identifiers

PMID31819116
PMCPMC6901481
OpenAlexW2994075906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.